LUNA 18
Alternative Names: LUNA-18; LUNA18 CapsuleLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Chugai Pharmaceutical
- Class Antineoplastics; Peptides
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (PO, Capsule)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in USA (PO, Capsule)
- 08 Sep 2021 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in USA (PO) (NCT05012618)